Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Income from Non-Controlling Interests (2022 - 2024)

Zentalis Pharmaceuticals (ZNTL) has 3 years of Income from Non-Controlling Interests data on record, last reported at -$28000.0 in Q1 2024.

  • For Q1 2024, Income from Non-Controlling Interests rose 34.88% year-over-year to -$28000.0; the TTM value through Dec 2024 reached -$28000.0, up 75.44%, while the annual FY2024 figure was -$28000.0, 75.44% up from the prior year.
  • Income from Non-Controlling Interests reached -$28000.0 in Q1 2024 per ZNTL's latest filing, down from -$22000.0 in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at -$12000.0 in Q3 2023 and bottomed at -$160000.0 in Q1 2022.
  • Average Income from Non-Controlling Interests over 3 years is -$49888.9, with a median of -$35000.0 recorded in 2022.
  • The widest YoY moves for Income from Non-Controlling Interests: up 87.88% in 2023, down 69.23% in 2023.
  • A 3-year view of Income from Non-Controlling Interests shows it stood at -$13000.0 in 2022, then tumbled by 69.23% to -$22000.0 in 2023, then fell by 27.27% to -$28000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Income from Non-Controlling Interests were -$28000.0 in Q1 2024, -$22000.0 in Q4 2023, and -$12000.0 in Q3 2023.